- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.04. | BIODLINK-B (01875): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 3 | HKEx | ||
| 28.04. | BIODLINK-B (01875): (1) RESIGNATION OF DIRECTORS AND CHAIRPERSON OF THE BOARD; (2) APPOINTMENTS OF DIRECTORS, CHAIRPERSON OF THE BOARD AND CHANGES IN ... | - | HKEx | ||
| 28.04. | BIODLINK-B (01875): ANNUAL REPORT 2025 | 2 | HKEx | ||
| BIODLINK INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 31.03. | BIODLINK-B (01875): JOINT ANNOUNCEMENT VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE OFFEROR FOR ... | - | HKEx | ||
| 18.03. | BIODLINK-B (01875): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025 | - | HKEx | ||
| 13.03. | BIODLINK-B (01875): JOINT ANNOUNCEMENT VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE OFFEROR FOR ... | 1 | HKEx | ||
| 05.03. | BIODLINK-B (01875): DATE OF BOARD MEETING | 1 | HKEx | ||
| 03.03. | BIODLINK-B (01875): CERTAIN UNAUDITED FINANCIAL INFORMATION FOR THE YEAR ENDED 31 DECEMBER 2025 | - | HKEx | ||
| 03.03. | BIODLINK-B (01875): CLARIFICATION ANNOUNCEMENT IN RELATION TO THE ANNOUNCEMENT PURSUANT TO RULE 3.8 OF THE TAKEOVERS CODE | - | HKEx | ||
| 11.02. | BIODLINK-B (01875): JOINT ANNOUNCEMENT DESPATCH OF COMPOSITE DOCUMENT RELATING TO VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED ... | 1 | HKEx | ||
| 11.02. | BIODLINK-B (01875): WHITE FORM OF SHARE OFFER ACCEPTANCE AND TRANSFER OF ORDINARY SHARE(S) IN THE ISSUED SHARE CAPITAL OF BIODLINK INTERNATIONAL COMPANY ... | 2 | HKEx | ||
| 11.02. | BIODLINK-B (01875): PINK FORM OF OPTION OFFER ACCEPTANCE AND CANCELLATION OF SHARE OPTIONS GRANTED BY BIODLINK INTERNATIONAL COMPANY LIMITED | 2 | HKEx | ||
| 11.02. | BIODLINK-B (01875): COMPOSITE OFFER AND RESPONSE DOCUMENT VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF ... | 1 | HKEx | ||
| 04.02. | BIODLINK-B (01875): JOINT ANNOUNCEMENT DELAY IN DESPATCH OF COMPOSITE DOCUMENT RELATING TO VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ... | 2 | HKEx | ||
| 19.01. | BIODLINK-B (01875): APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER | 1 | HKEx | ||
| 15.01. | EQS Newswire: Gelonghui: WuXi XDC issues positive profit alert, to acquire BioDlink in bid to strengthen ADC CDMO lead | 665 | EQS Group (EN) | EQS Newswire / 15/01/2026 / 12:50 UTC+8
January 14, 2026 - WuXi XDC has issued a positive profit alert for fiscal 2025 and announced a cash tender offer for BioDlink, whose shares were suspended... ► Artikel lesen | |
| 14.01. | BIODLINK-B (01875): JOINT ANNOUNCEMENT (1) VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE OFFEROR ... | 2 | HKEx | ||
| 31.12.25 | BIODLINK-B (01875): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 | 2 | HKEx | ||
| 29.12.25 | BIODLINK-B (01875): TRADING HALT | 1 | HKEx | ||
| 27.10.25 | BioDlink Biopharm Co., Ltd.: BioDlink Completes First International Shipment of Bevacizumab to Colombia | 308 | PR Newswire | Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death in Colombia [1].
This inaugural... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOVANT | 32,030 | +21,83 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| QIAGEN | 29,305 | -1,38 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 109,74 | +0,21 % | Inhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2026 Financial Results | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter... ► Artikel lesen | |
| EVOTEC | 4,772 | +0,68 % | Evotec zapft den Kapitalmarkt an | Evotec platziert Wandelanleihen über 116,1 Mio. EUR und finanziert damit das Transformationsprogramm "Project Horizon". Die Evotec SE hat sich frisches Kapital über den Wandelanleihemarkt gesichert.... ► Artikel lesen | |
| BIONTECH | 76,10 | -0,52 % | Ihre wichtigsten Termine: Alle Blicke auf: Fraport, Biontech, Nagarro, Freenet & Intercontinental Exchange | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Deutschland:... ► Artikel lesen | |
| RELAY THERAPEUTICS | 11,940 | -1,08 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies | Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-reported... ► Artikel lesen | |
| KEROS THERAPEUTICS | 9,910 | 0,00 % | Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent First Quarter 2026 Financial Results | LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| BICARA THERAPEUTICS | 20,050 | +0,10 % | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | ||
| VERADERMICS | 99,75 | 0,00 % | Veradermics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering | NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated ("Veradermics"), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics... ► Artikel lesen | |
| CG ONCOLOGY | 64,99 | +2,67 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| PROTAGONIST THERAPEUTICS | 99,03 | +0,67 % | Hedge Fund and Insider Trading News: Bill Ackman, Seth Klarman, David Einhorn, Michael Burry, Perbak Capital Partners, Charter Communications Inc (CHTR), Protagonist Therapeutics Inc (PTGX), and More | ||
| CENTURY THERAPEUTICS | 2,120 | 0,00 % | Warum Biotech-Aktien jetzt im Umbruch sind und Zelltherapie nicht nur bei BioNTech, Morphosys und Co. ein Thema ist. | ||
| PRAXIS PRECISION MEDICINES | 328,24 | +2,38 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| TECTONIC THERAPEUTIC | 27,210 | -0,29 % | Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights | TX45 APEX Phase 2 patient enrollment in PH-HFpEF is nearing completion with topline results anticipated in late Q4 2026 or early Q1 2027TX2100 advanced into Phase 1a healthy volunteer clinical trial... ► Artikel lesen | |
| ALTO NEUROSCIENCE | 20,490 | 0,00 % | Alto Neuroscience GAAP EPS of -$0.80 |
Das Unternehmen BIODLINK INTERNATIONAL CO LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODLINK INTERNATIONAL CO LTD finden Sie auf Wallstreet Online.